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Burkholderia pseudomallei is an important human pathogen that causes 
melioidosis. Infection is highly lethal and notoriously difficult to diagnose and 
treat. As such, it has tremendous bioterror potential and has been classified as a 
Tier 1 select agent by the Centers for Disease Control and the Department of 
Health & Human Services. One reason that B. pseudomallei is a successful 
pathogen is that it is surrounded by a high molecular weight capsular 
polysaccharide (CPS) comprised of mannoheptopyranose residues. CPS inhibits 
complement deposition, prevents phagocytosis, and greatly enhances virulence. 
Previous studies have indicated that antibodies targeting CPS have high 
therapeutic value and can be used to diagnose B. pseudomallei infection.  
The present work describes the development and characterization of 15 
monoclonal antibodies (mAbs) in an effort to further the understanding of how 
antibodies interact with B. pseudomallei CPS. We have generated two complete 
Immunoglobulin G (IgG) subclass families; subclass families are antibodies that 
have identical variable regions, but different constant regions, and thus different 
effector functions. We have determined that some of these mAbs are protective 
in a murine model of pulmonary melioidosis in a subclass-independent manner. 
In this study, protection appears to be a function of mAb binding affinity. 
Additionally, we determined that non-IgG3 mAbs are best for diagnosing active 
infection. Isolating a high affinity IgG3 and generating a subclass-switch family 




format. Thus, immunization strategies should focus on eliciting alternative IgG 
immune responses. Using this information, we have updated a prototype Active 
Melioidosis Detect™ Lateral Flow Immunoassay (AMD LFI) by replacing the 
original IgG3 mAb with a high affinity IgG1 mAb. This updated AMD LFI has 
increased sensitivity, is highly specific, and rapid; it can detect B. pseudomallei 
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 This work describes the development of a library of monoclonal antibodies 
(mAbs) to diagnose and/or treat Burkholderia pseudomallei infection. A brief 
introduction on each component of the research will be given, including pertinent 
information on B. pseudomallei and the disease it causes, melioidosis. 
Additionally, brief introductions on bacterial capsules, antibodies, and immunity 
will be given. Finally, laboratory diagnostic methods that incorporate antibodies 
will be covered, with an emphasis on lateral flow immunoassays. 
Endemicity and epidemiology of Burkholderia pseudomallei 
 B. pseudomallei is a soil-dwelling, gram-negative bacillus endemic to 
Southeast Asia and Northern Australia. It thrives in aqueous environments and its 
geographical distribution ranges from roughly 20 degrees north and south of the 
equator (1). This region is expanding as global climate conditions allow for more 
favorable B. pseudomallei replication; temperatures are staying warmer farther 
from the equator and monsoons are pushing farther inland (1). The bacterium is 
ubiquitous in endemic regions; it is so common that, by the age of 4, 80% of all 
Thai children have circulating antibodies against B. pseudomallei antigens (2).  
B. pseudomallei readily infects through contact with dermal abrasions, 
ingestion, or inhalation (3). It is an opportunistic pathogen and will not usually 
cause serious disease in healthy individuals. Predisposing factors are conditions 
that impair neutrophil function, including diabetes mellitus, thalassaemia, renal 




Patients with diabetes exhibit reduced neutrophil migration to sites of infection 
due to impaired regulation of TNF-α (5). In general, innate immunity mechanisms 
do not seem to contribute to patient survival. Instead, survival rates are 
correlated with high antibody titers to B. pseudomallei antigens (1).   
Diagnosis and treatment of B. pseudomallei infection 
B. pseudomallei is the causative agent of melioidosis and infects roughly 
21 out of every 100,000 people in Northeast Thailand. Infection is highly lethal, 
causing fatal sepsis in almost 50% of all patients in Thailand (6). Of the survivors, 
25% will relapse, which it thought to be caused from reactivation of latent B. 
pseudomallei reservoirs in internal organs. Melioidosis is the third most common 
cause of death from infectious disease in Northeast Thailand, behind human 
immunodeficiency virus (HIV) and tuberculosis. Even in Australia, where access 
to intensive therapy is more readily available, mortality rates are still as high 20% 
(6). Globally, there are an estimated 250,000 deaths each year attributed to 
melioidosis (personal communication Dr. Direk Limmathurotsakul). 
 B. pseudomallei infection is notoriously difficult to diagnose and treat. 
Melioidosis presents as a febrile illness and mimics the symptoms of many other 
diseases including tuberculosis and other influenza-like illness. The vast majority 
of patients present with pneumonia and/or bacteremia (7). Severity ranges from 
rapid onset septicemia to chronic infection. Patients usually experience a 7-10 
day incubation period before the onset of symptoms, however, there have been 




 Culturing patient samples and isolating B. pseudomallei is the gold 
standard for diagnosis of melioidosis, however, it is not an ideal method (10). It 
takes 7 to 10 days and has a low sensitivity (true positive rate); only about 60% 
of melioidosis cases are correctly identified via culture (10). This is partially due 
to the low numbers of bacteria that accumulate in patient blood (~1 CFU/mL) 
(11). Other diagnostic methods include the indirect hemagglutination assay (IHA) 
(12), immunochromogenic cassette test (ICT) (13), direct antigen enzyme-linked 
immunosorbent assay (ELISA) (14), immunofluoresence microscopy (IFA) (15), 
and polymerase chain reaction (PCR) (11). Much of the population in endemic 
regions is seropositive making IHA, ICT, and direct antigen ELISA very 
inaccurate. IFA and PCR are unreliable, again due to the low levels of bacteria 
that accumulate in patient blood. Additionally, the heme and human DNA found in 
blood can inhibit PCR (16). Rapid and accurate diagnosis is critical; delayed 
treatments allow the bacteria to disseminate to immune privileged sites and are 
associated with a higher likelihood of patient relapse (7, 17). 
 B. pseudomallei contains several chromosomally encoded genes that 
make it inherently resistant to the most commonly prescribed antibiotics, 
including macrolides, polymyxins, aminoglycosides, cephalosporins, and 
penicillins (17). Resistance mechanisms include exclusion of antibiotics, efflux of 
antibiotics, and enzymatic inactivation of the antibiotic (18). B. pseudomallei can 
even delete parts of its genome to develop additional antibiotic resistances during 




pseudomallei can delete a gene encoding the penicillin-binding protein 3, 
rendering it resistant to ceftazidime (19). The bacterium has multiple antibiotic 
tolerance mechanisms, including being an intracellular pathogen and possessing 
the ability to form biofilms (18). Due to the plethora of resistance strategies 
employed by B. pseudomallei, the current treatment regimen is complex, 
requiring multiple classes of antibiotics. This regimen is extremely difficult to 
complete, which explains the high lethality and relapse rates in resource-limited 
environments. The current recommendations for treatment of acute melioidosis 
require intravenous ceftazidime (or a carbapenem) every 12 hours for at least 2 
weeks to treat the initial infection, followed by oral co-trimoxazole and 
doxycycline, every 12 hours for at least 20 weeks in order to prevent relapse 
(20). 
 There are currently no licensed vaccines for B. pseudomallei infection. 
Ongoing approaches in development include subunit vaccines (21), attenuated 
live microorganisms (22), inactivated whole cells (23), B. pseudomallei DNA (24), 
membrane vesicles (25), and glycoconjugates (26, 27). Many of the vaccines in 
development show promise and can prolong the mean time-to-death in animal 
models, however, to date, none of these vaccine formulations have been able to 







Virulence factors and host response to B. pseudomallei 
  B. pseudomallei has adapted to survive in a wide variety of environments 
and hosts. It can grow at a wide pH range or lay dormant in times of nutrient 
deficiency and reawaken several years later (28, 29). B. pseudomallei resists the 
classical complement pathway and produces many extracellular effector 
molecules that allow it to thrive as an intracellular pathogen, including proteases, 
lipases, and phospholiphases (30). It also produces effector molecules that help 
it avoid host immune responses, including peroxidase and superoxide dismutase, 
which allow it to resist respiratory burst and reproduce inside macrophages and 
neutrophils (31). These effector molecules are delivered with bacterial type III 
and type VI secretion systems (32, 33).  
 Another very important virulence factor is the B. pseudomallei capsule. 
The bacterium is encapsulated with a high molecular weight capsular 
polysaccharide (CPS) comprised of an unbranched homopolymer of 1,3-linked 2-
O-acetyl-6-deoxy-β-D-mannoheptopyranose residues (34). CPS is required for 
virulence (35), it is a protective antigen (36, 37), and it is actively shed into 
patient samples during infection (38). It aids in cellular adhesion, inhibits 
complement, and inhibits phagocytosis (39). There are at least 25 genes in the 
CPS operon that encode for sugar biosynthesis, lipid biosynthesis, sugar 
transporters, and glycotransferases. Knockout of a subset of CPS biosynthetic 






 Capsules are a common virulence factor among many pathogenic bacteria 
and yeast, including Neisseria meningitidis (42), Klebsiella pneumoniae (43), 
Haemophilus influenzae (44), and Cryptococcus neoformans (45). Most capsules 
are comprised of polysaccharides. One notable exception is Bacillus anthracis, 
which is encapsulated with a polypeptide (poly-γ-D-glutamic acid) (46). Capsular 
structures are diverse and vary in sugar composition; however, they are all 
generally high molecular weight antigens comprised of several repeating 
epitopes.  
 The evolution of capsule development was likely the result of 
environmental selection; encapsulation aids in surviving hostile conditions. 
Capsular material is generally hydrophilic and prevents desiccation (47), 
antiphagocytic and prevents uptake by amoeba (47). Capsules are generally 
large and dense, making them antiviral; bacteriophages cannot easily penetrate 
capsules to interact with surface receptors (47). Degradation of the capsule in 
phage-resistant Streptococcus pneumoniae renders the bacterium phage-
sensitive (48). 
 These same factors contribute to bacteria survival in patients; capsules 
are almost always virulence factors. For example, removal of the capsule from K. 
pneumoniae renders the bacterium harmless at otherwise lethal doses in a 
murine model of K. pneumoniae pulmonary infection (43). Capsules are 




deposition on the bacterial surface and shield pathogen-associated molecular 
patterns (PAMPs) from the innate immune system (43). 
 Antibodies that target capsules are opsonic and protective in many cases, 
including B. pseudomallei infection. Antibodies reduce the capsule charge, 
making it less hydrophilic. This increases complement deposition and phagocyte 
uptake; phagocytes are assumed to be hydrophobic and antibodies lessen the 
repulsion between the two (47). However, capsular structures are only weakly 
immunogenic and do not elicit a robust, persistent humoral immune response. 
Capsular polysaccharides are T cell-independent type-2 antigens that activate B 
cells by multivalent cross-linking of antigen receptors (49). Antibodies generated 
this way are sialylated, causing them to interact with both the bacterium and the 
immune system in a very weak manner (50).  
B. pseudomallei as a potential bioweapon 
 Due to its high mortality rates and inherent resistance to common 
antibiotics, the CDC and HHS have classified B. pseudomallei as a Tier 1 Select 
Agent with a high bioterror potential. B. pseudomallei has never been 
weaponized, but the concern is not unfounded. It is believed that many countries 
have previously had an interest in biological weapons incorporating B. 
pseudomallei, including the former USSR, the USA, and Egypt (1). Additionally, a 
closely related species, B. mallei, has been used as a bioweapon on multiple 
occasions. During World War I, the Central Powers used B. mallei to infect 




intentionally infected human prisoners of war and successfully developed a 
system to contaminate water supplies with B. mallei (1). The bacterium has been 
used as recently as 1984 in the Russian war in Afghanistan (51). 
Antibodies 
 Antibodies are a structurally diverse group of glycoproteins used by the 
immune system to identify potential threats. They assist the immune system by 
binding to an antigen and neutralizing it (52, 53), tagging it for complement (54), 
or assisting in phagocytosis (55, 56). Also known as an immunoglobulin (Ig), 
antibodies contain binding regions, called paratopes, which bind to very specific 
targets called epitopes. An epitope is a structurally unique 3D molecular 
conformation found on an antigen. Antigens can be almost anything, but they are 
most commonly foreign microbes or molecules. There are some autoimmune 
disorders where antibodies target “self” antigens (i.e. rheumatoid arthritis) (57). 
Paratopes and epitopes are analogous to locks and keys; each paratope can 
(usually) bind to just one epitope.  
 Two types of lymphocytes secrete antibodies: B cells and memory cells. B 
cells are coated with membrane-bound antibodies, called B cell receptors (BCR), 
which allow them to bind specific antigens and produce antibodies against those 
antigens. BCR:antigen binding is not enough to stimulate antibody production; 
the B cell must also receive secondary signals. Secondary signals can come 
from a T cell (T cell-dependent activation), from the B cell’s own toll-like receptors 




BCRs in a multivalent fashion (T cell-independent type-2 activation) (58-60). 
Secondary signals are a regulatory mechanism that helps prevent B cells from 
making antibodies to “self” antigens (i.e. autoimmune disorders). Memory cells 
are a subset of B cells that expand upon reinfection and produce high 
concentrations of antibody to fight repeating infections.  
 Antibodies are Y-shaped molecules composed of two light chains and two 
larger heavy chains (Fig. 1). The tip of each arm is composed of the variable 
heavy (VH) and variable light (VL) chains. Together, these make up the variable 
region (FV), which designates the paratope of the antibody. There is incredible 
paratope diversity with over 109 possible combinations available (61). The rest of 
the antibody is made up of the constant light chain (CL) and the constant heavy 1, 
2, and 3 chains (CH1, CH2, CH3). The constant domain determines the antibody’s 
isotype. There is significantly less diversity in the constant region; in humans 
there are just five isotypes (IgM, IgD, IgG, IgA, and IgE). Each isotype contributes 
to immunity in a unique manner. For example, IgA antibodies are usually found in 
mucosal membranes while IgG antibodies are usually found in serum (62, 63). 
 Additionally, IgG has four subclasses (IgG1, IgG2, IgG3, IgG4) and IgA has 
two subclasses (IgA1, IgA2) (64). Antibody subclasses have identical FV regions, 
but slightly different heavy chain constant regions (Fig. 2). This means that 
subclass switch antibodies all have the same paratope, and thus bind to the 
exact same epitope, but with different binding characteristics and effector 




and phagocytic monocytes to greatly increase inflammation (65). Conversely, 
human IgG4 FC regions do not bind complement and interact with inhibitory 
receptors that dampen inflammation (65). Moreover, recent data has shown that 
human IgG1 antibodies are the only human subclass that can crosslink FC 
regions to increase immune activity (66).  
 Antibodies can be generated in vivo against specific targets by immunizing 
an animal with an antigen and stimulating that animal’s immune system. The 
animal will make polyclonal antibodies (pAbs) that can be purified from serum. 
PAbs are isolated as a mixture of antibodies produced from different circulating B 
cells and therefore can be of varying isotypes and subclasses. PAbs are a 
combination of several unique antibodies to a single antigen that can bind to 
multiple epitopes on the antigen. Because pAbs come from multiple B cell clones 
in vivo, there can be significant batch-to-batch variability, which can make pAbs 
difficult to characterize; however, this can also be of benefit. For example, pAbs 
can still bind to antigens that have minor alterations (i.e. glycosylation) because 
they cover multiple epitopes (67). 
  Conversely, monoclonal antibodies (mAbs) are produced from a single cell 
line and bind to just one epitope on the antigen. This makes them highly specific, 
reduces the chance of cross-reactivity, and makes them simpler to characterize. 
Additionally, mAbs can be screened based on isotype and affinity, which may be 
important depending on the downstream applications, such as therapeutics. For 




because IgG is abundant in serum, while an IgA would be used to target 
pathogens found in the mucosal membranes. However, this high specificity 
comes at a cost: mAbs take much longer to generate, require more technical 
skills to generate, and are much more expensive to produce (67). MAbs are 
highly desirable for applications when high specificity and reproducibility are 
important, like pharmaceuticals. There are currently several mAb therapies 
available, including treatments for rheumatoid arthritis (68), leukemia (69), and 
human respiratory syncytial virus (RSV) (70).  
MAbs can be generated by harvesting the animal’s B cells from the 
spleen. B cells cannot survive for long outside of the spleen and must be 
immortalized through a fusion with a mouse myeloma (tumor) cell (71). Fused 
cells of this type are called hybridomas. Hybridomas are isolated at single cell 
concentrations by limiting dilutions to ensure monoclonality before being grown in 
bioreactors to mass produce mAbs for purification. 
Active and passive immunity 
 Due to their protective nature, there has been a strong interest in using 
antibodies to prevent and treat disease. Vaccines are a form of active immunity 
where the immune system is primed to generate a persistent antibody response 
against specific pathogens; in the event of infection, the immune system has 
immunological memory and can rapidly fight the disease. Vaccines can be as 
simple as introducing heat-killed microorganisms or attenuated live 




undesirable to inoculate a person with whole cell bacteria because of toxins 
found in the cell membrane (i.e. lipopolysaccharides). In these scenarios, a 
vaccine may be comprised of just one or two subunits of the pathogen. Toxoids 
are inactivated toxins and are common subunit vaccines (i.e. tetanus). Capsular 
polysaccharides (CPS) are also commonly used to generate subunit vaccines. As 
previously mentioned, capsules by themselves are T cell-independent type 2 
antigens, thus weakly immunogenic and unable to elicit a strong humoral immune 
response. Therefore, a capsule is conjugated to an immunogenic toxoid or 
protein, transforming it into a T cell-dependent antigen, to elicit a potent and 
persistent humoral immune response. For example, the Haemophilus influenzae 
type 2 (Hib) vaccine is a conjugate of the capsular polysaccharide of H. 
influenzae to tetanus toxoid (74). 
 Passive immunization is the transfer of antibodies from one individual to 
another and can be used to treat disease when there is insufficient time for the 
infected patient’s immune system to develop antibodies on its own. Immunity via 
passive immunization is temporary; antibodies have a half-life of about 3 weeks 
and the recipient does not develop immunological memory (75). Passive transfer 
of antibody occurs naturally between a mother and offspring while the immune 
system is still developing. Antibodies are transferred across the placenta to 
protect the unborn fetus; after pregnancy, antibodies are transferred through 
breast milk. Passive immunity can be artificially induced by transferring 




antibody, to a non-immunized patient. For example, sera from patients who 
survived an Ebola virus infection can be used to treat infected individuals 
because antiserum potentially contains protective antiviral antibodies (76). 
Patients receiving antiserum have a risk of developing serum sickness, a 
potentially life-threatening allergic reaction to other proteins found in serum that is 
not their own (77). One way to avoid serum sickness is to passively transfer 
purified monoclonal antibodies. 
Lateral Flow Immunoassay 
 In addition to preventing and treating disease, antibodies can be used to 
diagnose disease. Due to their highly specific binding capabilities, antibodies can 
be used to determine exactly what pathogen is infecting a patient in order to 
provide a specific and targeted treatment. Currently, there are several types of 
diagnostic tests using antibodies, including enzyme-linked immunosorbent 
assays (ELISA), immunohistochemistry (IHC), and lateral flow immunoassays 
(LFI). The present study will focus on the LFI. 
 LFIs are rapid, single-use, point-of-care (POC) diagnostics. They require 
minimal amounts of patient sample for testing. LFIs are very user-friendly, 
requiring minimal equipment and training to operate effectively. They are 
inexpensive and extremely robust, in that they can be stored in high temperature 
and humidity settings without loss of potency (78). The most well known LFI is 
the home pregnancy test (79). LFIs confirm that presence or absence of an 




pregnancy test the LFI confirms the presence of human chorionic gonadotropin in 
the urine of pregnant women. 
 The LFI quickly moves a liquid sample containing the analyte of interest 
through 4 zones: i) sample application pad, ii) sample conjugation pad, iii) test & 
control lines, and iv) absorbent pad (Fig. 3). The sample conjugation pad and test 
& control lines are characterized by antibodies that interact with the analyte of 
interest in a specific manner to ultimately create a sandwich assay; zones are 
sequentially connected with a porous membrane that facilitates liquid flow. 
Membranes come in various pore sizes and materials, including nitrocellulose 
(79), nylon (80), or polyethylene (81); membranes are chosen based on the size 
and characteristics of the analyte being tested. A brief overview of the zones will 
follow. 
The patient sample is first applied to the sample application pad. Capillary 
action draws the analyte to the sample conjugate pad where it can interact with 
labeled antibodies. Labels must be small so they do not obstruct flow through the 
membrane and must be detectable. Common labels include colloidal gold (79), 
carbon black (82), and europium (83). Colloidal gold and carbon black have the 
advantage of being visually detectable with the naked eye. Europium is 
fluorescent and requires a fluorometer, however, it is generally more sensitive 
(83). 
Capillary action continues and the analyte:labeled antibody complex is 




antibody:analyte:labeled-antibody sandwich that can detected. The intensity of 
the response is directly proportional to the amount of analyte in the sample. If 
there is no analyte in the sample, the labeled-antibody will pass right over the 
immobilized antibody and no visual sandwich will be made. A mAb that binds to 
other mAbs is immobilized at the control to confirm the liquid has flowed all the 
way through the strip. The total test time is about 10 minutes (83). 
Summary 
 B. pseudomallei is an opportunistic pathogen and the causative agent of 
melioidosis, a disease that causes significant morbidity and mortality in endemic 
regions. The bacterium is considered to have high bioterror potential due to its 
ease of culture from the soil, the relatively small numbers of bacteria needed for 
infection, and its resistance to commonly prescribed antibiotics. There are 
currently no vaccines available to prevent B. pseudomallei infection and current 
diagnostic methods are cumbersome and inaccurate. Like many other 
pathogenic microorganisms, B. pseudomallei surrounds itself with a high 
molecular weight capsular polysaccharide (CPS) that contributes greatly to 
bacterial virulence and pathogenicity. The CPS is shed into infected patient 
serum and urine. 
 Antibodies are highly specific immune molecules that are generated in 
response to pathogen infection in order to neutralize and clear threats. Due to 
their highly specific and protective nature, we can use antibodies to both 




library of mAbs, including 2 full subclass-switch IgG families, targeting the CPS of 
B. pseudomallei for the diagnosis and treatment of melioidosis. Each mAb has 
been thoroughly characterized to facilitate the selection of mAbs that may provide 
protection against B. pseudomallei in vivo. In addition, our work has lead to the 
development of the Active Melioidosis Detect™ Lateral Flow Immunoassay for 
the rapid diagnosis of melioidosis (AMD LFI). The AMD LFI is currently 
undergoing validation at a variety of locales across the globe in both clinical and 






Figure 1. Antibodies are comprised of two heavy chains and two light chains. 
The heavy chain consists of 3 constant domains and 1 variable domain; the light 
chain consists of 1 constant domain and 1 variable domain. Together, the 
variable heavy chain and the variable light chain make up the variable region 






Figure 2. Antibody subclasses have identical variable regions and all bind to the 







Figure 3. Schematic of a lateral flow immunoassay (LFI). A liquid sample 
containing the analyte of interest is applied to sample pad and capillary action 
pulls the sample through to the conjugate pad. Here, gold-labeled antibodies bind 
with the analyte. Next, the analyte:labeled antibody complex flows to the test line 
where immobilized antibodies will interact with the analyte to create a sandwich 
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Immunoglobulin G3 (IgG3) is the predominant antibody isotype and 
subclass in response to polysaccharide antigens in mice. This specific 
subclass seems better suited than other subclasses to bind to 
polysaccharide antigens commonly displayed on bacteria and yeast. The 
improved binding appears to be due to the fact that murine IgG3 antibodies 
have increased avidity through fragment crystallizable (FC) region cross-
linking that is not seen in other IgG antibody subclasses. In order to further 
investigate this phenomenon, we have analyzed the binding 
characteristics of two IgG monoclonal antibody (mAb) subclass families 
that bind to the capsular polysaccharide (CPS) of Burkholderia 
pseudomallei. The first subclass family originated from an IgG3 hybridoma 
cell line (3C5); the second family was generated from an IgG1 cell line 
(2A5). When the FC region of the 3C5 IgG3 is removed by proteolytic 
cleavage, the resulting F(ab’)2 fragments exhibit significantly decreased 
affinity compared to the full-length mAb. Similarly, when the FC region is 
subclass-switched, the resulting IgG1, IgG2b, and IgG2a antibodies all 
exhibit significantly decreased affinity and protection in a murine model of 
pulmonary melioidosis. This dramatic decrease in affinity and protection is 
not seen when the parent 2A5 IgG1 is switched to an IgG2b or IgG2a, 






 Polysaccharide capsules are known to contribute to bacterial 
virulence by inhibiting complement activation and preventing phagocytosis 
(1-5). They are high molecular weight antigens with repeating epitopes 
that are displayed on the bacterial and fungal cell surface (6-9). Anti-
capsular antibodies are an important mechanism for host defense, thus 
capsules are appealing vaccine candidates; however, polysaccharide 
antigens do not illicit a robust humoral immune response by themselves. 
Robust humoral immunity is induced in a T-cell dependent (TD) manner 
(10), however, polysaccharides can bypass this mechanism and stimulate 
B-cells by cross-linking multiple cell surface antigen receptors. T-cell 
independent (TI) responses produce a much weaker humoral immune 
response (11). One way to generate lasting humoral immunity to a 
polysaccharide is to conjugate it to a highly immunogenic protein or toxoid 
(12-14). For example, the Haemophilus influenzae capsule elicits a much 
stronger immune response when it is conjugated to tetanus toxoid (12). 
 IgG subclass in response to polysaccharide antigens is restricted. 
In humans, IgG2 is the predominant antibody response to polysaccharide 
antigens (15); in rats, IgG2c is the predominant response (16). In mice, 
IgG3 is produced almost exclusively to polysaccharide antigens, while the 
other subclasses are generated in response to other antigens (17-19). For 




families are comprised of antibodies that have identical variable regions 
(FV) but different heavy chain constant regions; at a very low frequency, 
antibodies spontaneously convert into different downstream subclasses 
through constant heavy chain gene recombination in vivo. We have 
adapted a technique to isolate subclass-switch hybridoma clones in vitro, 
which is based on sequential sib selection (20, 21). This allows for efficient 
study of subclass-switch mAb families. 
 Seminal research by Greenspan and colleagues established the 
enhanced binding of murine IgG3 to polysaccharides over that of non-IgG3 
subclass-switch mAbs containing identical variable regions (22-24).  
Specifically, it was shown that the antibodies in a murine IgG subclass 
family (IgG3èIgG1èIgG2b), which did not include an IgG2a, interact with 
the same Group A streptococcal antigen in very different ways. Murine 
IgG3 bound cooperatively and thus possessed a higher affinity than IgG1 
or IgG2b. Similarly, IgG3-derived F(ab’)2 fragments did not show 
cooperative binding and bound with a much lower affinity, similar to that of 
the IgG1 and IgG2b (22). In an additional study, Cooper et al. generated a 
partial subclass family (IgG3èIgG1) to the lipopolysaccharide (LPS) of 
Pseudomonas aeruginosa. IgG3 showed superior binding to both purified 
LPS and whole bacteria (24). Similarly, the IgG3 variant of a complete 
subclass family exhibits greater binding affinity to the capsular polypeptide 




binding affinity was a result of alterations in the CH2 and CH3 domains, 
which comprise the FC region in IgG molecules. When altering this same 
murine IgG3 FC region by engineering human chimeric antibodies (chAbs), 
the resulting chAbs have significantly reduced binding affinities for the 
capsular polypeptide (25). Taken together, this data suggests that 
changes in the FC region can alter antibody-antigen interactions. 
 The goal of this study was to determine if the murine IgG3 FC region 
contributes to the affinity of antibodies binding to the capsular 
polysaccharide (CPS) of Burkholderia pseudomallei. Subclass-switch 
families of mAb 3C5 (IgG3èIgG1èIgG2bèIgG2a) and mAb 2A5 
(IgG1èIgG2bèIgG2a) were generated. Both mAb families bind CPS; mAb 
3C5 was isolated from a mouse immunized with heat-killed whole B. 
pseudomallei cells (26). MAb 2A5 was generated from a mouse 
immunized with CPS covalently linked to bovine serum albumin (BSA); 
this glycoconjugate was previously shown to induce high titers of CPS- 
specific IgG antibodies in mice (14). MAb 3C5 is a relatively high affinity 
murine IgG3 that has been shown to provide passive protection in a 
murine model of pulmonary melioidosis (27). MAb 2A5 is a murine IgG1 
with a similar affinity to mAb 3C5 IgG3.  
 The results of this study suggest that antibody affinity is an 
important factor in protection, and that the IgG3 FC region significantly 




repeating epitopes (such as polysaccharides). Removal of the FC region 
from IgG3 mAb 3C5 by proteolytic cleavage substantially decreases the 
affinity of the resulting F(ab’)2 fragment. Similarly, switching the FC region 
from an IgG3 to an IgG1, IgG2b, or IgG2a results in a substantial decrease in 
affinity. These results were determined via surface plasmon resonance 
(SPR), and also confirmed with a direct antigen binding ELISA.  
Furthermore, IgG3 mAb 3C5 provides superior protection over the 
subclass-switch variants in a murine model of pulmonary melioidosis. This 
change in affinity and drop in protection is not seen when IgG1 mAb 2A5 
switches to an IgG2b or IgG2a. Taken together, the IgG3 FC region 
contributes to antibody binding to B. pseudomallei CPS resulting in 






Materials and Methods 
Immunization of mice and production of mAbs. Generation of mAb 
3C5 IgG3 has been described (27). Briefly, B. pseudomallei strain 1026b 
was grown overnight at 37 ºC in brain heart infusion broth. Bacteria were 
heat inactivated at 80 ºC for 2.5 hours. BALB/c mice were immunized via 
intraperitoneal (i.p.) injections with 2 x 108 heat-inactivated bacteria every 
two weeks for eight weeks total. An ELISA was used to assess antibody 
titers to B. pseudomallei. A final boost was administered three days prior 
to splenectomy. Hybridoma cells were produced as previously described 
(28). Western blot analysis was performed to identify hybridoma cell lines 
that were producing mAbs reactive with purified CPS.  
 MAb 2A5 IgG1 was produced using CPS conjugated to bovine 
serum albumin (BSA) (14). BALB/c mice were immunized via i.p. injections 
with 5 µg of CPS-BSA every two weeks, for six weeks total. Antibody titers 
were measured via ELISA (see below) and hybridoma cell lines were 
generated as above.  
 A modified protocol based on the method of Spira et al. (20) was 
used to isolate subclass-switch families as previously described (20, 21). 
Briefly, subclass-switch hybridomas were identified via ELISA and plated 
at limiting dilution until the cell line was completely sublined (20). Cell lines 
were grown in Integra CL 1000 culture flasks (Integra Biosciences) with 




mercaptoethanol, 20 mM HEPES, 1 mM sodium pyruvate, and 15% fetal 
bovine serum (FBS) (low IgG). Antibodies were purified by affinity 
chromatography over a protein-A column. 
F(ab’)2 fragments.  F(ab’)2 fragments were generated from digestion of 
full-length mAbs with pepsin from porcine gastric mucosa (Sigma). 
Summarily, mAbs (5 mg/mL) were incubated with shaking at 37 °C for 30 
min with pepsin at a final concentration of 0.2 µg/mL in 20 mM NaOAc, pH 
4.4. Next, 10% (v/v) of Tris (2M) was used to stop the reaction. F(ab’)2 
fragments were purified over a Superose 12 (GE Healthcare) molecular 
sieve column. 
MAb variable region sequencing.  MAb heavy and light chain variable 
regions were sequenced as previously described (21). Briefly, total mRNA 
was isolated from each hybridoma cell line with a RNeasy Mini Kit 
(QIAGEN). cDNA was synthesized using a First Strand cDNA Synthesis 
Kit (Thermo Scientific) and amplified with a Mouse Ig-Primer Set 
(Novagen). PCR products were TA cloned into the pGem-T vector 
(Promega), and sequenced at the Nevada Genomics Center. Two 
independent clones were sequenced for each experiment. 
Western blot. One µL of a 10x concentrated B. pseudomallei 1026b 
lysate, 1.1 x 105 cfu of B. mallei China 7 (BEI), 8 x 106 cfu of B. 
thailandensis E264 (BEI), or 0.5 µg purified CPS were incubated with 1 




separated by sodium dodecyl sulfate-12% polyacrylamide gel 
electrophoresis (SDS PAGE) (BioRad) at 160 V for 1 hr, followed by 
transfer to a nitrocellulose membrane (BioRad) via a TransBlot Turbo 
(BioRad). Membranes were blocked in TBS+0.1% Tween 20, 5% milk 
overnight at 4 °C (blocking solution). Membranes were then probed with 
mAbs at 0.1 µg/mL diluted in blocking solution for 1 hr while rocking at 
room temperature. Membranes were washed 3 times for 15 min with 
TBS+0.1% Tween 20 and mAb binding was detected with peroxidase-
conjugated goat anti-mouse kappa chain antibody (Southern Biotech) 
diluted 1:10,000 in blocking solution and incubated for 30 min at room 
temperature. Membranes were washed 3 additional times and binding was 
detected with SuperSignal West Femto Chemiluminescent Substrate 
(Pierce). Binding was visualized with a Chemidoc imaging system 
(BioRad). 
Surface plasmon resonance.  Binding affinity was determined by surface 
plasmon resonance (SPR) with a BIAcore X100 (GE Healthcare). Purified 
CPS was benzoquinone-activated and conjugated to biotin as previously 
described (29), and immobilized onto a streptavidin (SA) sensor chip at 30 
response units (RU). A second flow cell was unmodified and used for 
reference subtractions. Affinity was evaluated with mAbs diluted in HBS-
EP+ running buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 




serial dilutions of mAb were injected over the immobilized CPS at 30 
µL/min for 60 s, followed by 120 s of passive dissociation. The sensor chip 
surface was regenerated between each concentration with 10 mM HCl, pH 
1.5. Dissociation constants (KD) were calculated using BIAevaluation 
software (GE Healthcare).  
ELISA. Polystyrene plates (Thermo Scientific) were coated for 90 min at 
37ºC with 0.005% (w/v) Poly-L-Lysine (Sigma) diluted in PBS. Plates were 
washed with PBS and incubated overnight with 4 µg/mL of purified CPS 
(14). Next, plates were washed with PBS+0.05% Tween 20 and blocked 
with PBS+0.05% Tween 20, 5% milk (blocking solution) at 37 ºC for 90 
min. MAbs (or mouse sera) were two-fold serially diluted across the wells 
in blocking solution (from 2000 µg/mL) and the plates were incubated at 
37 ºC for 90 min. MAb binding was detected with peroxidase-conjugated 
goat anti-mouse kappa chain antibody (or peroxidase-conjugated goat 
anti-mouse IgG antibody) (Southern Biotech) diluted in blocking solution at 
1:10,000 and incubated for 90 min, followed by TMB peroxidase substrate 
(KPL) for 30 min. The enzymatic reaction was stopped by adding 100 µL 
of 5% o-phosphoric acid to each well and the optical density was 
determined by measuring absorbance at 450 nm. Each experiment was 
completed in duplicate. To calculate the antibody concentration that 




a four-parameter logistics curve fit was applied using Sigma Plot 11.0 
(Systat Software Inc.). 
Animal protection studies. Intranasal challenge experiments were 
performed as previously described under ABSL-3 conditions (27). Briefly, 
six week old female BALB/c mice were injected with 1 mg of mAb by the 
i.p. route 18 h prior to challenge. B. pseudomallei 1026b at 7100 cfu/0.1 
mL (21 LD50) was introduced to each mouse by the intranasal (i.n.) route. 
Mice were monitored 42 days post-infection for weight loss, lack of activity, 
matted fur, and other clinical symptoms. Statistics were performed using a 
log-rank (Mantel-Cox) test with an adjusted Bernferroni-corrected 
threshold using GraphPad Prism 6.0. Infected control mice were 
administered PBS instead of mAb. Survivors were necropsied and internal 
organs were examined for abscess growth. Spleens were homogenized in 
1 mL of brain-heart infusion (BHI)/10% glycerol and 0.1 mL of the 
homogenate was plated on a BHI-gentamicin plate. 
Ethics statement. All studies were carried out in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The Animal Care and Use 
Committees at the University of Nevada, Reno (Protocol A07/08-16) and 






We previously generated the IgG3 mAb, 3C5, from BALB/c mice 
immunized with heat-inactivated whole B. pseudomallei (26); notably, we 
generated the IgG1 mAb, 2A5, in a different manner, from BALB/c mice 
immunized with purified CPS conjugated to BSA (9). Subclass-switch 
families of both mAbs were generated with a modified sequential sib 
selection protocol (20). In order to verify that the heavy and light chain 
variable regions were identical for all subclasses, total mRNA was isolated 
from each hybridoma cell line and used for cDNA synthesis and PCR 
amplification. PCR products were ligated into pGEM-T and sequenced 
(data not shown). 
Western blot analysis was used to verify that all of the generated 
mAbs bind to CPS. CPS is a high molecular weight antigen comprised of 
an unbranched polymer of -3)-2-O-acetyl-6-deoxy-β-d-manno-
heptopyranose-(1- residues that produce a characteristic smear via 
Western Blot (9). The IgG3 variant of mAb 3C5 and the IgG1 variant of 
mAb 2A5 both bind to the same proteinase K-resistant high molecular 
weight antigen found in B. pseudomallei, B. mallei and purified CPS 
preparations. Additionally, neither mAb binds to B. thailandensis, which 
lacks CPS (30) (Fig. 1). Subclass-switching mAb 3C5 yielded mAbs that 
bind to CPS via Western blot, but require much higher concentrations to 




2A5 generated mAbs that bound to CPS at similar signal levels as the 
parent IgG1 (data not shown). 
In order to elucidate the relationship between subclass FC region 
and mAb binding, the binding kinetics of each mAb were determined by 
SPR with a BIAcore X100. Purified CPS was conjugated to biotin (29) and 
immobilized on a streptavidin-coated sensor chip. Total immobilization of 
CPS was 30 RU. MAbs were injected over a 60 second pulse and a 
titratable increase in RU was observed (Fig. 2). The steady state model 
from BIAevaluation software was applied to each graph to determine the 
dissociation constant for each mAb (Fig. 3). The calculated binding affinity 
of each mAb is in Table 1. Notably, the subclass-switch variants of mAb 
3C5 have much lower affinity for CPS than the parent IgG3. In order to 
determine if this was due to the change in FC region, F(ab’)2 fragments 
were produced from the 3C5 IgG3; the F(ab’)2 fragments had even lower 
affinity compared to the subclass-switches. Importantly, the calculated 
binding affinity of the subclass-switch variants of mAb 2A5 remained 
constant, which led us to believe that, while changes in the IgG3 FC region 
appear to affect affinity, changes in the IgG1 FC region do not. 
An ELISA was performed to compare the relative antigen binding 
characteristics of the 3C5 and 2A5 subclass families (Fig. 4). Purified CPS 
was plated in the solid phase at 4 µg/mL and 2-fold serial dilutions of 




the plot represents a different mAb subclass. The 3C5 subclass-switch 
mAbs require much higher concentrations to generate the same response 
as the IgG3, whereas the 2A5 subclass-switch mAbs all perform similarly 
to each other. These plots were used to calculate the half-maximal 
effective concentration value (EC50), which is the antibody concentration 
that generates a response halfway between the baseline and maximum; 
smaller values correlate with a higher efficacy (Table 1). The calculated 
EC50 value for the IgG3 variant of mAb 3C5 was 0.9 µg/mL, whereas the 
calculated EC50 values for the subclass-switch mAbs were well over 10-
fold higher. The calculated EC50 value of the IgG1 variant of mAb 2A5 was 
about 2-fold lower than mAb 3C5, indicating that it has a higher efficacy. 
Similar to the affinity analysis, the calculated EC50 values of the 2A5 
subclass variants remained comparable to the parent IgG1. 
We previously determined that the IgG3 variant of mAb 3C5 was 
protective in a murine model of pulmonary melioidosis, where 75% (6/8) of 
immunized mice survived inoculation with 15 LD50 of B. pseudomallei 
1026b (27). We wanted to investigate whether a change in FC region 
would affect the ability of CPS mAbs to afford protection in vivo, so each 
mAb was assessed as previously described (Fig. 5) (27). Mice were 
passively immunized with 1 mg of mAb and subsequently challenged with 
21 LD50 of B. pseudomallei 1026b by the intranasal route. All infected mice 




The IgG3 variant of mAb 3C5 protected 25% (2/8) of the infected mice with 
a mean time to death (MTD) of 31 days (Table 2). This appears to 
contradict our previous study, where mAb 3C5 protected 75% of infected 
mice; however, it is important to note that the mice in this challenge 
received a much higher dose of bacteria than in our original study. The 
increased bacterial load dramatically accelerated how quickly the control 
mice got sick; in our first study, control mice survived until day four, 
whereas in the current study control mice survived only to day 2.  
The IgG1 and IgG2a variants of mAb 3C5 provided similar levels of 
protection to the IgG3 but with much shorter MTDs of 4 and 4.5 days 
respectively; the IgG2b variant offered slightly higher protection than the 
IgG1 and IgG2a at 37.5% (3/8) and a MTD of 16 days. Similar to the trends 
seen in the SPR/affinity and ELISA experiments, all of the 2A5 subclass-
switch mAbs provided similar levels of protection; in fact, the 2A5 mAbs all 
offered increased levels of protection compared to the 3C5 family, even 
the IgG3 variant (Table 2).  
 In addition to survival, each mAb’s effect on spleen cfu and 
abscess formation was determined. Spleen cfu were recorded and splenic 
abscesses were counted in surviving mice only. Both were assumed to 
occur in mice that died before day 42 in order to allow for statistical 
analysis (Table 2). 87.5% (7/8) of the mice immunized with the IgG3, IgG1, 




(5/8) of the mice immunized with the IgG2b variant showed spleen cfu. 
None of the survivors developed splenic abscesses as determined by 
gross examination. Of the mice immunized with the 2A5 subclass 
antibodies, 50% (4/8) of the mice immunized with the IgG1 variant had 
spleen cfu, while 71.4% (5/7) and 62.5% (5/8) of the mice immunized with 
the IgG2b and IgG2a variants showed spleen cfu, respectively. Only 2 of the 






 Many pathogenic microorganisms produce capsular structures, 
including Haemophilus influenzae (31), Neisseria meningitidis (32), 
Bacillus anthracis, and Cryptococcus neoformans (33). These capsules 
are comprised of polysaccharides or, in the case of Bacillus anthracis, a 
polypeptide (34). Capsules are antiphagocytic and are generally required 
for virulence (35). Antibodies that target capsules are opsonic and 
protective in many cases (35). As such, capsules are ideal vaccine 
targets, however, most capsular polysaccharides do not elicit a strong 
immune response, especially in infants and young children (36). Capsular 
polysaccharides are high molecular weight antigens comprised of several 
identical repeating units, making them T-cell independent type 2 antigens 
(TI-2) (37). They can activate B-cells by multivalent cross-linking of B-cell 
antigen receptors, which produces a very specific antibody response (11). 
Mice generally produce IgG3 in response to capsular polysaccharides (17-
19); humans generally produce IgG2 (15). As such, it is important to 
elucidate the immunochemistry between antibodies and microbial 
capsules so that we may develop effective vaccines and 
immunotherapeutics that elicit the appropriate humoral response against 
encapsulated pathogenic microbes. 
 There have been multiple studies showing mAbs can provide 




been no studies to date comparing different antibody subclasses (38-43). 
Subclass-switch families are antibodies with identical FV regions but 
different heavy chain constant regions, thereby making them invaluable for 
determining how the FC region contributes to binding. This study builds on 
previous work showing that antibodies subclass-switch antibodies bind to 
their target with a different specificity and affinity, despite having identical 
FV regions (23, 44).  In one study, altering the CH1 domain of antibodies 
targeting HIV-1 gp41 resulted in variable-region identical mAbs that bound 
to completely different epitopes (44). In a separate study, IgG2a derived 
F(ab’)2 fragments bound stronger to C. neoformans GXM than the intact 
IgG2a or even the IgG3 variant, indicating that structural changes to the 
CH1 domain contribute to antibody affinity (45). Additionally, our group has 
shown that changes in the CH2 and CH3 domains can also affect antibody 
binding affinity.  Replacing any of the IgG3 CH domains with IgG2b CH 
domains greatly reduced the antibody’s ability to bind to γDPGA (21). 
In the current study, we generated two different subclass-switch 
families: one that originated from a high affinity IgG3 mAb (3C5) and one 
that originated from a high affinity IgG1 mAb (2A5). Removal of the FC 
region of mAb 3C5 by proteolytic cleavage generates IgG3 F(ab’)2 
fragments with reduced affinity by SPR and a 300-fold increase in EC50 by  
ELISA. Similarly, subclass-switching mAb 3C5 from an IgG3 to an IgG1 




Subclass-switching the IgG1 variant to IgG2b or IgG2a results in antibodies 
with a similar affinity and binding capacity to the IgG1. Subclass-switching 
mAb 2A5 from an IgG1 variant into an IgG2b or IgG2a variant yields mAbs 
with similar affinities and EC50 values to the IgG1. Taken together, this 
strongly suggests that the drop in affinity and binding capacity is related to 
the IgG3 FC region. Altering the FC region of an IgG1 mAb does not seem 
to impact antibody binding. 
 Previous studies have shown that the IgG3 variant of mAb 3C5 is 
protective in an animal model of pulmonary melioidosis (27). To assess if 
reduced affinity and binding capacity would impact animal protection, we 
administered groups of mice with mAbs of different subclasses from the 
same family.  As in our previous study, passive immunization with the IgG3 
variant increased survival rates. In the previous study, the IgG3 variant of 
mAb 3C5 protected 75% (6/8) of infected mice, while in this study, only 
25% (2/8) of infected mice were protected (27). However, it is important to 
note that the mice in the current study where challenged with more 
bacteria: 21 LD50 (resulting in 7100 cfu/mouse) as compared to 15 LD50 
(5000 cfu/mouse) in the first study. This increased bacterial load caused 
control mice to become moribund by day 2; in the first study, control mice 
survived until day 4.  
Passive immunization with the IgG1 and IgG2a subclass-switch 




these groups had significantly shorter MTD (4 and 4.5 days, respectively) 
indicating that they were not nearly as effective. These findings are 
supported by recent results published by our group (21). In this study, 
mice were immunized with a subclass-switch family of mAbs targeting the 
capsule of B. anthracis. B. anthracis has a polypeptide capsule comprised 
of poly-gamma-D-glutamic acid (γDPGA) that shares many characteristics 
with polysaccharide capsules, such as being a TI-2 antigen (46). In these 
studies, only the IgG3 variant was protective in a murine model of 
pulmonary anthrax (21).  
 Next, we wanted to determine if the decreased protection afforded 
by the different subclasses was due to their reduced affinity or inherently 
related to mAb subclass. Murine IgG3 antibodies have the unique ability to 
cross-link their FC domains and bind cooperatively; this can even occur 
between two different IgG3 mAbs that bind to two independent 
polysaccharide antigens (47). Cooperative binding does not occur if the FC 
region is removed or switched to another subclass (23), and we wondered 
if cooperative binding was necessary for protection. Mice were passively 
immunized with the high affinity 2A5 subclass-switch family of mAbs. The 
IgG1, IgG2b, and IgG2a variants of mAb 2A5 provided 87.5% (7/8), 71.4% 
(5/7), and 75% (6/8) protection of infected mice, respectively, indicating 
that protection is not dependent on IgG3 FC-FC interactions. There were 




anthracis and Cryptococcus neoformans suggest that non-IgG3 capsule-
specific mAbs may be protective (48-51). In a murine model of pulmonary 
anthrax, both IgG3 and non-IgG3 mAbs significantly increase mouse 
survival rates (48, 49). Similarly, the higher affinity mAbs afforded more 
protection than the lower affinity mAb (48). Additionally, in a murine model 
of cryptococcal meningitis, IgG1 mAbs provide the highest rates of 
protection, even when the IgG3 variant has a higher affinity (50, 51). In 
fact, the IgG3 variant can even enhance virulence in some cases (52). 
 The results of this study show that mAbs targeting the CPS of B. 
pseudomallei are protective in a murine model of pulmonary melioidosis. 
At this dose (1 mg per mouse), protection is independent of IgG subclass; 
the high affinity 2A5 subclass mAbs all provided significant levels of 
protection. One hypothesis for the decreased protective efficacy of the 
3C5 subclass-switch mAbs is a decrease in affinity. Subclass-switching of 
mAb 3C5 from an IgG3 to any other subclass generates an antibody with 
significantly reduced binding capacity. MAb 3C5 has high affinity as an 
IgG3 variant; however, this could reflect avidity effects due to FC-FC 
crosslinking.  Removing the IgG3 FC via proteolytic cleavage or altering the 
FC region via subclass-switching prevents FC-FC interactions, which 
reduces the apparent affinity. Meanwhile, mAb 2A5 originates with a high 
affinity as an IgG1, without FC-FC crosslinking, and thus, did not lose 




subclass variants were equally protective and the 3C5 variants were less 
protective and had a much shorter MTD when compared to the IgG3. IgG3 
is the primary IgG response to polysaccharides in mice (17-19); FC-FC 
interactions may help the antibodies bind more strongly until affinity-
matured antibodies of other subclasses can be generated.  
In summary, this study suggests that IgG3 FC regions play an 
important role in antibody binding by increasing affinity and avidity. 
Altering or removing the FC region reduces antibody-binding capacity and 
diminishes protection. However, protection is not solely dependent on the 
IgG3 FC region; a murine model of melioidosis indicates that high affinity 
mAbs of any subclass may be a viable therapeutic for B. pseudomallei 
infection. The mAbs in this study were not able to provide sterilizing 
immunity, however, they did extend MTD in mice inoculated with a very 
high dose of B. pseudomallei, and therefore, could potentially be used as 
an adjunct therapy to antibiotics for melioidosis. There have been several 
melioidosis vaccine studies in animals (53), none of which have resulted in 
sterile immunity. CPS is a potential vaccine candidate (27, 54), therefore, 
anti-CPS immunization strategies should prioritize eliciting robust, high 
affinity antibody titers. Future studies include testing the mAbs in a dose-
dependent manner in order to elucidate potential differences between 
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Table 1. Summary of antibodies generated for this study. 







3C5 IgG3 Vh6 IgK V19/28 0.28 0.0011 73 0.9±0.03 
 IgG1 Vh6 IgK V19/28 0.016 0.0024 1,460 18±1.7 
 IgG2b Vh6 IgK V19/28 0.027 0.0024 790 12±0.8 
 IgG2a Vh6 IgK V19/28 0.043 0.0041 550 12±1.0 
 F(ab’)2d - - 0.038 0.0059 2,100 383±130 
2A5 IgG1 Vh6 IgK V21 1.8 0.024 43 0.37±0.02 
 IgG2b Vh6 IgK V21 1.1 0.012 36 0.36±0.03 
 IgG2a Vh6 IgK V21 0.72 0.0093 58 0.76±0.08 














Figure 1. B. pseudomallei (Bp) 1026b, B. mallei (Bm) China 7, purified 
CPS, or B. thailandensis (Bt) E264 were incubated with proteinase-K, 
separated by SDS PAGE, and subsequently transferred to a nitrocellulose 
membrane. Membranes were probed with 0.5 µg mAb and binding was 
detected with an HRP-conjugated goat anti-mouse kappa chain antibody. 
MAbs 3C5 (IgG3) and 2A5 (IgG1) bind to a high molecular weight, 
proteinase-K resistant antigen found in B. pseudomallei, B. mallei, and 
purified CPS. MAbs do not interact with B. thailandensis, which lacks CPS. 
The subclass-switch families bind with similar results (data not shown). 
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Figure 2. Binding specificity of subclass-switch family mAbs and 3C5 IgG3 
F(ab’)2 fragments given as a function of response generated over time. A 
BIAcore X100 instrument was used to determine the affinity of each mAb 
for CPS. Purified CPS was conjugated to biotin and immobilized on a SA 
sensor chip. MAb binding was analyzed by injecting eight samples (2-fold 
serial dilutions (0.33-333 or 12-3,333 nM) for 60 s, followed by 120 s of 
passive dissociation. Note the magnitude of the response for 3C5 IgG3 



















Figure 3. Binding affinity of subclass-switch family mAbs and 3C5 IgG3 
F(ab’)2 fragments given as a function of response generated by 
concentration. The steady state model from BIAevaluation software was 
applied to each graph in Fig 2 to determine the dissociation constant (KD) 
of each mAb. A smaller KD corresponds to a higher affinity. Note the 
magnitude of the response for 3C5 IgG3 compared to all other mAbs, even 





Figure 4. Direct antigen binding ELISA comparing 3C5 IgG3 and 2A5 IgG1 
binding with subclass with switch family mAbs. CPS was immobilized in the solid 
phase at 4 µg/mL. 2-fold serial dilutions of mAb or F(ab’)2 were added in the fluid 
phase starting at 2,000 µg/mL and mAb binding was detected with an HRP-
conjugated goat anti-mouse kappa chain antibody. There is a significant 
decrease in binding when altering or removing the IgG3 Fc region, whereas 


























Figure 5. Protection levels afforded by each mAb in mice passively 
immunized prior to infection with B. pseudomallei 1026b. BALB/c mice 
were administered 1 mg of mAb by the i.p. route; control mice received 
PBS. After 18 hours, i.n. challenge was performed with 21 LD50 of B. 
pseudomallei. Mice were observed daily for 42 days. The p values of 






Figure 6. Weight profiles of passively immunized mice in Fig 5. All 
infected mice showed reduced activity, a temporary decrease in weight, 
and moderate illness. Mice immunized with the 3C5 subclass family mAbs 
were more likely to succumb during later stages of infection, indicated by 
short time period of diminished clinical symptoms and an increase in 
weight before a sharp decrease in weight and subsequent death. A  
indicates mouse death. 





























Table 2. Survival and gross pathology of passively immunized mice infected with B. pseudomallei 1026b. 
mAb Subclass Mean time-to-death 
Survived 
(p value)b 
(+) Spleen cfuc 
(p value)d 




3C5 IgG3 31 2/8 (< 0.01) 7/8 (= 1) 8,0 0/2 
 IgG1 4 2/8 (< 0.01) 7/8 (= 1) 22,0 0/2 
 IgG2b 16 3/8 (< 0.01) 5/8 (= 0.2) 0,0,0 0/3 
 IgG2a 4.5 1/8 (< 0.01) 7/8 (= 1) 0 0/1 
2A5 IgG1 UD 7/8 (< 0.01) 4/8 (= 0.07) ND,0,0,3,ND,0,0 2/7 
 IgG2b UD 5/7 (< 0.01) 5/7 (= 0.2) 0,0,T,7,5 0/6 
 IgG2a UD 6/8 (< 0.01) 5/8 (= 0.2) 0,2,368,5,0,0 0/6 
aMean time-to-death in days; UD indicates too few deaths to calculate. 
bp value vs. controls determined by Kaplan-Meier survival plots by log-rank (Mantel-Cox) test. 
cPositive spleen cfu was determined on survivors and assumed to occur In mice that died before study endpoint. 
dp values vs. controls determined by Fisher’s exact test. 
eSpleen cfu was assessed on survivors only.  
 ND indicates an abscess was present, but cfu counts were not determined, T indicates too numerous to count. 
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Burkholderia pseudomallei, the causative agent of melioidosis, 
causes significant morbidity and mortality across Southeast Asia. The 
bacterium’s high virulence comes in part from its capsule; it is 
encapsulated with a high molecular weight capsular polysaccharide (CPS) 
that inhibits phagocytosis, inhibits complement deposition, and is essential 
for virulence. Previously, our laboratory determined that low levels of CPS 
are shed into patient sera and urine and identified CPS as a possible 
diagnostic marker for B. pseudomallei infection. In a preliminary study, we 
produced a CPS-specific IgG3 monoclonal antibody (mAb), 3C5, and 
successfully incorporated it into a prototype Active Melioidosis Detect™ 
Lateral Flow Immunoassay (AMD LFI) through a collaboration with InBios 
International, Inc. While successful, the prototype had background issues 
attributed to IgG3 self-association that would potentially produce false 
positive results. This led us to pursue the development of additional 
antibodies of alternate IgG subclasses. We have isolated an IgG1 mAb, 
4C4, which has reduced background reactivity compared to mAb 3C5. 
Additionally, this new mAb displays a high affinity for CPS and can detect 
lower concentrations of CPS in solution. Use of the improved mAb may 
allow for a LFI with improved clinical sensitivity. An updated LFI 






 Burkholderia pseudomallei is a soil-dwelling, gram-negative 
bacillus. It is the causative agent of melioidosis, a highly prevalent disease 
in Southeast Asia and Northern Australia. B. pseudomallei infects roughly 
21 out of every 100,000 people in Northeast Thailand each year, and of 
those infected, only about 50% survive the infection (1). Survival rates are 
higher in Australia, where intensive therapy is more readily available; here, 
80% of all melioidosis patients survive (2). Even so, survival does not 
guarantee immunity to repeat infections. Roughly 20% of all melioidosis 
survivors will suffer a relapse infection and contract the disease a second 
(or third) time (3). While there have been several melioidosis vaccine 
studies in animals, none of them have been effective at eliciting sterilizing 
immunity (4). 
Melioidosis is a febrile illness that is incredibly difficult to diagnose 
because it mimics the symptoms of so many other diseases. Infected 
patients may present flu-like symptoms, pneumonia, and bacteremia (5). 
There is usually a 7-10 day incubation period in infected individuals; 
however, some cases can take several years to manifest (6, 7). Rapid 
diagnosis of melioidosis is critical; B. pseudomallei is resistant to the most 
commonly prescribed antibiotics and any delay in treatment is correlated 




standard for diagnosis of melioidosis, however, it may take 7-10 days to 
confirm infection via culture, and it is only about 60% accurate (9). 
B. pseudomallei produces a high molecular weight capsular 
polysaccharide (CPS) comprised of an unbranched homopolymer of 
mannoheptopyranose residues (10). The CPS is responsible for B. 
pseudomallei persistence in the blood by preventing the deposition of 
complement factor C3b and inhibiting phagocytosis (11). As such, it is 
essential for virulence (12). Melioidosis survival rates are correlated with 
high antibody titers against CPS (13); antibodies to capsules can act as an 
intermediary by assisting complement deposition and promoting 
phagocytosis (14). Unfortunately, capsules are generally T-cell 
independent type-2 (TI-2) antigens (15). They activate B-cells by 
multivalent cross-linking of antigen receptors, eliciting a weak, non-
persistent humoral immune response (16). 
Our laboratory previously developed a diagnostic biomarker 
discovery platform, in vivo microbial antigen discovery (InMAD) (17). 
InMAD studies showed that B. pseudomallei CPS is shed into patient 
samples, and we identified the CPS as a potential biomarker for the 
diagnosis of melioidosis (17). We generated a murine IgG3 monoclonal 
antibody (mAb) and developed a prototype Active Melioidosis Detect™ 
Lateral Flow Immunoassay (AMD LFI). The prototype AMD LFI is able to 




ng/mL to diagnose melioidosis in 15 minutes or less (18). While very 
successful, the prototype suffers from background issues attributed to 
IgG3 self-association. IgG3 is the predominate response to 
polysaccharides in mice (19-21), and research has shown that this 
antibody subclass can bind cooperatively to multivalent antigens (22-24). 
 The goal of the present study was to improve upon a prototype 
AMD LFI by generating a library of high affinity mAbs against the CPS of 
B. pseudomallei in order to eliminate background issues and increase 
sensitivity. Our results demonstrate that mAb 4C4 is an ideal candidate for 




Materials and Methods 
Immunization of mice and production of mAbs.  Generation of mAb 
3C5 has been described (25). MAbs were produced using CPS 
conjugated to bovine serum albumin (BSA) (26). BALB/c mice were 
immunized via intraperitoneal (i.p.) injections with 5 µg of CPS-BSA every 
two weeks for six weeks total. An ELISA was used to determine antibody 
titers to B. pseudomallei CPS (see below). A final boost with purified CPS 
was administered three days prior to splenectomy. Hybridoma cells were 
produced as previously described (27). Western blot analysis was done to 
identify hybridoma cell lines that were producing mAbs reactive with 
purified CPS. Cell lines were grown in Integra CL 1000 culture flasks 
(Integra Biosciences) with RPMI media containing 50 µM 2-
mercaptoethanol, 20 mM HEPES, 1 mM sodium pyruvate, and 15% FBS 
(low IgG). Antibodies were purified by affinity chromatography over a 
protein A column.  
Western blot. 1 µL of a 10x concentrated B. pseudomallei 1026b lysate 
(Dr. Richard Bowen, Colorado State University), 1.1 x 105 cfu of B. mallei 
China 7 (BEI), 8 x 106 cfu of B. thailandensis E264 (BEI), or 0.5 µg purified 
CPS were incubated with 1 volume of proteinase K at 3.3 mg/mL for 1 hr 
at 60 °C. Next, samples were separated by sodium dodecyl sulfate-12% 
polyacrylamide gel electrophoresis (SDS PAGE) (BioRad) at 160 V for 1 




TransBlot Turbo (BioRad). Membranes were blocked in TBS+0.1% Tween 
20, 5% milk overnight (blocking solution) at 4 °C. Membranes were then 
probed with mAbs diluted at 0.1 µg/m in blocking solution while rocking at 
room temperature for 1 hr. Membranes were washed for 15 min, 3 
separate times, with TBS+0.1% Tween 20 and mAb binding was detected 
with peroxidase-conjugated goat anti-mouse kappa chain antibody 
(Southern Biotech) diluted 1:10,000 in blocking solution and incubated for 
30 min at room temperature. Membranes were washed 3 additional times 
and binding was detected with SuperSignal West Femto 
Chemiluminescent Substrate (Pierce). Binding was visualized with 
Chemidoc Instruments (BioRad). 
Surface plasmon resonance. Binding affinity was determined using 
surface plasmon resonance (SPR) with a BIAcore X100 (GE Healthcare). 
Purified CPS was benzoquinone activated and conjugated to biotin as 
previously described (29), and immobilized onto a streptavidin (SA) sensor 
chip at 30 response units (RU). A second flow cell was unmodified and 
used for reference subtractions. Affinity was evaluated with mAbs diluted 
in HBS-EP+ running buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 
and 0.05% surfactant P20) at a range of 0-333 nM. 2-fold serial dilutions of 
mAb were injected over the immobilized CPS at 30 µL/min for 60 s, 




regenerated between each concentration with 10 mM HCl, pH 1.5. Affinity 
was determined using BIAevaluation software (GE Healthcare).  
Direct antigen enzyme-linked immunosorbent assay (ELISA). 
Polystyrene plates (Thermo Scientific) were coated for 90 min at 37ºC with 
0.005% (w/v) Poly-L-Lysine (Sigma) diluted in PBS. Plates were washed 
with PBS and incubated overnight with 4 µg/mL of purified CPS (26). Next, 
plates were washed with PBS+0.05% Tween 20 and blocked with 
PBS+0.05% Tween 20, 5% milk (blocking solution) at 37 ºC for 90 min. 
MAbs (or mouse sera) were serial diluted across the wells in blocking 
solution, starting at 2000 µg/mL, and the plates were incubated at 37 ºC 
for 90 min. MAb binding was detected with peroxidase-conjugated goat 
anti-mouse kappa chain antibody (or peroxidase-conjugated goat anti-
mouse IgG antibody) (Southern Biotech) diluted in blocking solution at 
1:10,000 and incubated for 90 min, followed by TMB peroxidase substrate 
(KPL) for 30 min. The enzymatic reaction was stopped by adding 100 µL 
of 5% o-phosphoric acid to each well and the optical density was 
determined by measuring absorbance at 450 nm. Each experiment was 
completed in duplicate. To calculate the antibody concentration that 
induces a response halfway between baseline and maximum (EC50 value), 
a four-parameter logistics curve fit was applied using Sigma Plot 11.0 




Antigen capture enzyme-linked immunosorbent assay (ELISA). 
Antigen capture ELISA was performed as previously described (17). In 
summary, antibodies were conjugated to horseradish peroxidase (HRP) 
with Pierce EZ-Link Plus Activated Peroxidase (Thermo Scientific) 
following the manufacturer’s protocol. Polystyrene plates (Thermo 
Scientific) were coated overnight at room temperature with 2 µg/mL of 
unlabeled mAb. Plates were washed with PBS+0.05% Tween 20 and 
blocked with PBS+0.05% Tween 20, 5% milk (blocking solution) at 37 ºC 
for 90 minutes. Purified CPS was serially diluted in blocking solution and 
incubated at 37 ºC for 90 minutes. HRP-conjugated mAbs were diluted in 
blocking solution and added to wells at a final concentration of 4 µg/mL or 
at a 1:10,000 dilution and incubated at room temperature for 90 minutes. 
MAb binding was detected with tetramethylbenzidine (TMB) peroxidase 
substrate (KPL) for 30 minutes. The enzymatic reaction was stopped with 
5% o-phosphoric acid and the optical density was determined by 
measuring absorbance at 450 nm. Each experiment was completed in 
duplicate. To calculate limit of detection (LOD) values, data was 
normalized in SoftMax Pro at an OD450 value of 0.3 (Molecular Devices). 
AMD LFI construction. AMD LFIs were prepared as previously described 
(18). In short, mAbs were sprayed onto the test line on a nitrocellulose 
membrane. Goat anti-chicken IgY was sprayed onto the same membrane 




was conjugated to 40 nm gold nanoparticles and dried in the conjugate 
pad. The sample pad, conjugate pad, and membrane were all assembled 
in an overlapping fashion atop a plastic back. 
AMD LFI sample preparation and testing. Five-fold serial dilutions of 
purified CPS (25-0.008 ng/mL) were made in 150 µL of chase buffer, 
human urine, or human serum and added directly to the sample pad. 
Images were taken after 15 minutes. The AMD LFI was shown to 5 
independent parties and the limit of detection was determined as the 
lowest value that all 5 people indicated seeing a red test line. 
 Bacterial colonies were tested as previously described (18). Briefly, 
bacteria were streaked for isolation on brain-heart infusion (BHI) agar and 
incubated at 37 ºC overnight. An entire colony was suspended in 2 drops 
of lysis buffer and added directly to the sample pad, followed by 3 drops of 
chase buffer. Images were taken after 15 minutes. 
Ethics statement. All studies were carried out in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The Animal Care and Use 
Committees at the University of Nevada, Reno (Protocol A07/08-16) 






MAb 3C5 (IgG3) was generated as previously described (25). IgG1 
mAbs were generated from BALB/c mice immunized with purified CPS 
conjugated to BSA (26). Splenocytes from immunized mice were fused 
with myeloma cells to generate mAb-secreting hybridomas. Total mRNA 
was isolated from each hybridoma cell line and used for cDNA synthesis 
and PCR amplification. PCR products were ligated into pGEM-T and 
sequenced to ensure that the variable region of each mAb in the library is 
unique. 
 All 8 mAbs were verified to bind to CPS via Western Blot; CPS is a 
produces a very characteristic smear at high molecular weights via 
Western Blot (10). All mAbs bound at similar concentrations to a 
Proteinase K-resistant high molecular weight antigen found in B. 
pseudomallei and Burkholderia mallei. MAbs also bound to purified CPS. 
MAbs did not bind to Burkholderia thailandensis lysate, which lacks CPS 
(Fig 1) (30). 
In order to elucidate the binding characteristics of each mAb in the 
library, the affinities were determined with SPR with a BIAcore X100. 
Purified CPS was conjugated to biotin (29) and immobilized on a 
streptavidin-coated sensor chip. Total immobilization of CPS was 30 RU. 
A titratable increase in RU was observed following a 60 second pulse of 




the BIAevaluation software was applied to determine the dissociation 
constant (KD) of each mAb (Fig 3). The calculated binding affinity of each 
mAb is in Table 1. MAbs 2A5, 1A2, and 4C4 all bound to CPS more 
strongly than our original mAb 3C5, however, mAb 3C5 exhibited a much 
greater response. 4C4 has the greatest binding affinity in the library with 
an observed KD of 12 nM, whereas mAb 3B4 had the lowest calculated KD 
at 139 nM. MAbs 1D3, 2B3, and 1D4 had KD values too low to accurately 
assess. 
Next, a direct antigen ELISA was performed to further assess the 
binding characteristics of mAbs 2A5, 1A2, 4C4 and 3B4 when compared 
to our original mAb 3C5 (Fig 4). Purified CPS was bound in the solid 
phase at 4 µg/mL and 2-fold serial dilutions of the mAbs were diluted in 
the fluid phase starting at 2,000 µg/mL. Each line on the plot represents a 
different mAb. These plots were used to calculate the half maximal 
effective concentration value (EC50), which is the antibody concentration 
that generates a response halfway between the baseline and maximum; 
smaller values correlate with a higher potency (Table 1). Similar to the 
affinity data, mAb 4C4 had the lowest EC50 value, at 0.16 µg/mL while 3B4 
had the highest EC50 value at 22 µg/mL. 
Additionally, sandwich ELISAs were performed in order to 
determine how the mAbs interact with each other and with CPS in the 




phase at 2 µg/mL and 2-fold serial dilutions of CPS were diluted in the 
solid phase starting at 640 ng/mL. Next, each mAb was conjugated to 
HRP and diluted in the fluid phase at 4 µg/mL. Each line of the plot 
represents a different mAb; the same mAb was used for both capture and 
detection. These plots were used to calculate the limit of detection (LOD) 
of each mAb combination in order to determine the least amount of CPS 
required for a signal; a lower LOD means we could theoretically diagnose 
B. pseudomallei infection earlier in infected patients (Table 1). Because of 
the high levels of background with mAb 3C5, data had to be normalized to 
calculate the LOD. The LOD was considered to be twice the background 
levels, or an OD450 signal of 0.3. MAb 4C4 in the capture and detection 
phases showed the lowest LOD at 0.25 ng/mL, followed by our original 
mAb 3C5 at 0.36 ng/mL. Interestingly, mAbs 2A5 and 1A2 showed a 
higher calculated LODs than mAb 3C5, at 1.56 and 0.72 ng/mL 
respectively, even though they had higher affinities. MAb 3B4 has a 
calculated LOD at 0.70 ng/mL, despite having the lowest affinity of the set. 
Additional ELISAs were performed with different combinations of mAbs in 
the capture and detection phases; even still, mAb 4C4 in both the capture 
and detect phases produced the lowest limit of detection overall (data not 
shown).  
Sample LFIs for each mAb were constructed as previously 




Different combinations of mAbs in the capture (control line) and detection 
(gold conjugated) phases were assembled and the limit of detection was 
assayed for each combination (data not shown). The limit of detection was 
defined as the lowest concentration at which 5 independent parties verified 
seeing a positive line. MAb 4C4 applied to both the capture and detection 
phases showed the lowest limit of detection at 0.04 ng/mL, a 5-fold greater 
limit of detection when compared to the original 3C5 AMD LFI prototype 
(Fig 6). Human serum and urine samples were spiked with purified CPS in 
order to verify that human samples would not interfere with the updated 
AMD LFI.  
 The updated LFIA was tested against multiple bacteria commonly 
seen in the soil to verify it would not cross-react and generate false 
positive results (Table 2). Nine distinct Burkholderia cepacia complex 
(BCC) bacteria were tested. BCC bacteria are soil-dwelling bacteria that 
are important human pathogens, however, they generally only infect 
patients with underlying lung disease, such as cystic fibrosis (31). The 
updated AMD LFI did not react with 8 of the samples, but did interact 
weakly with B. stabilis, which produces minimal CPS (12). Additionally, the 
AMD LFI did not react with 9 common gram-positive bacteria or 5 common 
gram-negative bacteria.  
 Next, the AMD LFI was also tested against 41 unique strains of B. 




broad range of infectious strains (Table 2). The AMD LFI was reactive with 
40/41 strains of B. pseudomallei and all 3 strains of B. mallei, but not B. 
thailandensis (which does not produce a capsule) (30).  
 Finally, the AMD LFI was tested against 20 unique human serum 
and urine samples to verify it would not react with individuals not infected 





 LFIs are becoming increasingly popular and are used to diagnose 
several diseases, including HIV infection, malaria, coronary artery disease, 
avian influenza, and community-acquired pneumonia (32, 33). They are 
inexpensive, user-friendly, and very rapid. LFIs require minimum patient 
sample for testing and can accommodate a variety of sample types, 
including saliva, urine, serum, and pus. They are sensitive, with limits of 
detection comparable to other diagnostic methods and can be read 
without any equipment (18, 33). This makes them ideal in both resource 
poor and point-of-care settings where high costs are prohibitive and 
access to training is limited.  
 The current diagnostic methods available for B. pseudomallei 
infection suffer from low sensitivity and require expensive equipment, 
among other drawbacks. For example, immunofluorescence assays (IFA) 
(34) and polymerase chain reactions (PCR) (35) require equipment and 
facilities that are not readily available in Northeast Thailand. This lead to 
the development of indirect hemagglutination assays (IHA) (36) and 
immunochromogenic cassette tests (ICT) (37) as inexpensive alternatives 
for rural areas. However, much of the population in endemic areas is 
seropositive for B. pseudomallei, making the presence of antibodies in 




 The AMD LFI avoids this problem by detecting B. pseudomallei 
CPS directly, an antigen that is only found during active infection. 
Additionally, CPS is a necessary virulence factor; mutations that prevent 
the biosynthesis of CPS greatly attenuate the bacteria (39, 40). The 
original prototype AMD LFI was constructed with a murine IgG3 and was 
highly successful; it could detect CPS levels as low as 0.2 ng/mL (18). 
However, it had levels of background that could be misinterpreted for a 
positive result. This was attributed to self-aggregation phenomena seen in 
murine IgG3 antibodies (22-24), thus, we sought to improve the AMD LFI 
by developing and screening a library of anti-CPS mAbs of different 
isotypes and subclasses. During the screening process, an IgG1 mAb, 
4C4, had a higher affinity, lower EC50 value, and lower limit of detection 
when compared to the other mAbs in the library, including the original mAb 
3C5. As such, mAb 4C4 was used to construct an updated AMD LFI. 
Importantly, the updated AMD LFI resolves the background issues 
seen in our prototype. Additionally, it can detect 5-fold lower levels of CPS 
than our original prototype, meaning that can possibly be diagnose B. 
pseudomallei infection much earlier than before. It was reactive with 41 
out of 42 strains of B. pseudomallei, 3 out of 3 strains of B. mallei and only 
reacted very weakly with 1 near neighbor strain of bacteria tested. The 




operon and produces the same capsule, albeit in significantly smaller 
quantities (12).  
The results from this study suggest that non-IgG3 murine mAbs are 
ideal for the LFI format and immunization strategies should focus on 
eliciting a strong IgG1 immune response. Isolating a high affinity IgG3 and 
producing an IgG1 by subclass switch does not seem like an acceptable 
alternative; when mAb 3C5 was subclass-switched to an IgG1, the affinity 
dropped significantly and the new variant performed very poorly by ELISA 
(Chapter 1). Thus, immunization strategies should focus on eliciting an 
alternative immune response. Furthermore, IgM mAbs seem to be poor 
candidates. We isolated two IgM mAbs and both reacted with CPS very 
poorly in vitro. This was not unexpected, as IgM antibodies are typically 
rapidly generated, low-affinity first responders that have not had the 
opportunity to affinity mature (41). 
 The updated AMD LFI incorporating mAb 4C4 is currently being 
tested at various sites across the globe in both clinical and environmental 
settings. It is currently undergoing a 24 Month Diagnostic Challenge with 
the Defense Threat Reduction Agency (DTRA) where it is being tested for 
sensitivity and stability at the Navy Research Laboratory (NRL). Future 
directions include optimizing the testing procedure for patient samples and 
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Table 1. Summary of antibodies generated for this study. 











3C5 IgG3 0.28 0.0011 73 0.9±0.03 0.36 
4C4 IgG1 0.0025 0.0024 1,460 0.16±0.01 0.25 
2A5 IgG1 1.8 0.0024 790 0.36±0.02 1.56 
1A2 IgG1 0.0009 0.0041 550 0.51±0.03 0.72 
3B4 IgG1 0.0002 0.0059 2,100 22±1.4 0.70 
1D3 IgG1 - - - - - 
2B3 IgM - - - - - 
1D4 IgM - - - - - 






Figure 1. B. pseudomallei (Bp) 1026b, B. mallei (Bm) China 7, purified 
CPS, or B. thailandensis (Bt) E264 were incubated with proteinase-K, 
separated by SDS PAGE, and subsequently transferred to a nitrocellulose 
membrane. Membranes were probed with 0.5 µg mAb and binding was 
detected with an HRP-conjugated goat anti-mouse kappa chain antibody. 
All mAbs bind to a high molecular weight, proteinase-K resistant antigen 
found in B. pseudomallei, B. mallei, and purified CPS. MAbs do not 
















Figure 2. Binding specificity of mAbs given as a function of response 
generated over time. A BIAcore X100 instrument was used to determine 
the affinity of each mAb for CPS. Purified CPS was conjugated to biotin 
and immobilized on a SA sensor chip. MAb binding was analyzed by 
injecting eight samples (2-fold serial dilutions (0-333 nM) for 60 s, followed 
by 120 s of passive dissociation. Note the magnitude of the response for 
3C5 IgG3 compared to all other mAbs. 

























































Figure 3. Binding affinity of subclass-switch family mAbs and 3C5 IgG3 
F(ab’)2 fragments given as a function of response vs. mAb concentration. 
The steady state model from BIAevaluation software was applied to each 
graph in Fig 2 to determine the dissociation constant (KD) of each mAb. A 
smaller KD corresponds to a higher affinity. Note the magnitude of the 
response for 3C5 IgG3 compared to all other mAbs, even the resultant 













Figure 4. Direct antigen binding ELISA comparing binding of all mAbs. 
CPS was immobilized in the solid phase at 4 µg/mL. 2-fold serial dilutions 
of mAb were added in the fluid phase starting at 2,000 µg/mL and mAb 
binding was detected with an HRP-conjugated goat anti-mouse kappa 














Figure 5. Sandwich ELISA comparing CPS detection capabilities of 
various mAbs. Purified mAb was immobilized in the solid phase at 2 
µg/mL. 2-fold serial dilutions of purified CPS were added in the fluid phase 
starting at 640 ng/mL. HRP conjugated mAb was used in the detection 
phase. MAb 4C4 demonstrated the lowest limit of detection (0.25 ng/mL). 
Note the high levels of background generated by mAb 3C5, possibly due 





Figure 6. LOD comparison of the original 3C5-3C5 prototype with the 
updated 4C4-4C4 AMD LFI. 5-fold dilutions of purified CPS were diluted in 
chase buffer starting at 25 ng/mL and applied to the sample pad of the (A) 
original 3C5-3C5 or (B) new 4C4-4C4 LFI. Results were imaged after 15 
minutes. The LOD was the lowest concentration at which 5 independent 
parties verified seeing a positive line. The updated 4C4-4C4 AMD LFI has 
a 5-fold greater sensitivity than the original 3C5-3C5 prototype when 
evaluated in this manner. 
(A) Purified CPS (ng/mL) on 3C5-3C5 Prototype 
  25        5          1       0.2      0.04    0.008   Neg 
(B) Purified CPS (ng/mL) on updated 4C4-4C4 





Table 2. 4C4-4C4 LFI analytical reactivity and specificity. 
   
Bacterial isolate Strain designation Lateral flow result 
Burkholderia cepacia PC783 Negative (-) 
Burkholderia cenocepacia HI2718 Negative (-) 
Burkholderia vietnamensis PC259 Negative (-) 
Burkholderia multivorans HI2229 Negative (-) 
Burkholderia anthina AU1293 Negative (-) 
Burkholderia ambifaria HI2464 Negative (-) 
Burkholderia dolosa FTU0645 Negative (-) 
Burkholderia pyrocinia BCII Negative (-) 
Burkholderia stabilis HI2210 Weakly positive (+) 
Burkholderia stabilis ATCC LMG 14294 Weakly positive (+) 
   
Burkholderia thailandensis E264 Negative (-) 
   
Streptococcus viridans — Negative (-) 
Streptococcus pyogenes — Negative (-) 
Streptococcus agalactiae — Negative (-) 
Streptococcus bovis — Negative (-) 
Streptococcus faecalis — Negative (-) 
   
Staphylococcus xylosus — Negative (-) 
Staphylococcus epidermidis — Negative (-) 
Staphylococcus aureus — Negative (-) 
Staphylococcus saprophyticus — Negative (-) 
   
Citrobacter freundii — Negative (-) 
Pseudomonas aeruginosa — Negative (-) 
Enterobacter aerogenes — Negative (-) 
Proteus vulgaris — Negative (-) 
Escherichia coli — Negative (-) 





Table 2. Continued. 
   
Bacterial isolate Strain name/DASH # Lateral flow result 
Burkholderia pseudomallei 1026b Positive (+) 
Burkholderia pseudomallei Bp82 Positive (+) 
Burkholderia pseudomallei Bp0029 Positive (+) 
Burkholderia pseudomallei Bp0033 Positive (+) 
Burkholderia pseudomallei Bp0034 Positive (+) 
Burkholderia pseudomallei Bp0035 Positive (+) 
Burkholderia pseudomallei Bp0049 Positive (+) 
Burkholderia pseudomallei Bp0056 Positive (+) 
Burkholderia pseudomallei Bp0065 Positive (+) 
Burkholderia pseudomallei Bp0071 Negative (-) 
Burkholderia pseudomallei Bp0072 Positive (+) 
Burkholderia pseudomallei Bp0082 Positive (+) 
Burkholderia pseudomallei Bp0084 Positive (+) 
Burkholderia pseudomallei Bp0096 Positive (+) 
Burkholderia pseudomallei Bp0097 Positive (+) 
Burkholderia pseudomallei Bp0098 Positive (+) 
Burkholderia pseudomallei Bp0099 Positive (+) 
Burkholderia pseudomallei Bp0101 Positive (+) 
Burkholderia pseudomallei Bp0114 Positive (+) 
Burkholderia pseudomallei Bp0115 Positive (+) 
Burkholderia pseudomallei Bp0121 Positive (+) 
Burkholderia pseudomallei Bp0122 Positive (+) 
Burkholderia pseudomallei Bp0123 Positive (+) 
Burkholderia pseudomallei Bp0127 Positive (+) 
Burkholderia pseudomallei Bp0128 Positive (+) 
Burkholderia pseudomallei Bp0129 Positive (+) 
Burkholderia pseudomallei Bp3539 Positive (+) 
Burkholderia pseudomallei Bp3570 Positive (+) 
Burkholderia pseudomallei Bp3671 Positive (+) 





Table 2. Continued. 
   
Bacterial isolate Strain name/DASH # Lateral flow result 
Burkholderia pseudomallei Bp3999 Positive (+) 
Burkholderia pseudomallei Bp4000 Positive (+) 
Burkholderia pseudomallei Bp4001 Positive (+) 
Burkholderia pseudomallei Bp4003 Positive (+) 
Burkholderia pseudomallei Bp4137 Positive (+) 
Burkholderia pseudomallei Bp4151 Positive (+) 
Burkholderia pseudomallei Bp4154 Positive (+) 
Burkholderia pseudomallei Bp4160 Positive (+) 
Burkholderia pseudomallei Bp4162 Positive (+) 
Burkholderia pseudomallei Bp4164 Positive (+) 
Burkholderia pseudomallei Bp4169 Positive (+) 
   
Burkholderia mallei AGD0001147 Positive (+) 
Burkholderia mallei AGD0001235 Positive (+) 
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 Capsules are important virulence factors that are produced by many 
pathogenic microbes, including B. pseudomallei and B. mallei. Capsules are 
antiphagocytic and prevent complement deposition on the surface of the 
bacterium (39, 47). Antibodies that target the capsule enhance phagocytosis and 
complement deposition, making them a critical part of any host defense against 
an encapsulated pathogen (47). There are several examples where patient 
survival rates correlate with high antibody titers against capsules (1, 84-86). 
Capsules are high molecular weight antigens that are comprised of several 
repeating epitopes. As such, they are T cell-independent type-2 antigens, are 
poorly immunogenic, and do not elicit a robust humoral immune response. 
Additionally, capsules are structurally diverse and unique to each organism; 
immunity to one capsule type does not confer immunity to other capsule types. 
Despite their incredible importance, there are relatively few studies to explain the 
molecular interactions between antibodies and capsules. The goal of the present 
study was to develop a library of monoclonal antibodies, including two full IgG 
subclass families, targeting the B. pseudomallei capsule in order to elucidate in 
vitro correlates of protective antibodies. Additionally, these antibodies have been 
incorporated into an Active Melioidosis Detect™ Lateral Flow Immunoassay 
(AMD LFI) in order to rapidly detect B. pseudomallei infection in endemic areas. 
 Antibodies have been used to treat disease since the late 1800’s when 




immunized guinea pigs could be used treat human diphtheria (87). Serum 
therapy became very popular, with a treatment for tetanus being developed 
shortly thereafter (87). More recently serum therapy has been used to treat Ebola 
hemorrhagic fever (76).  
 Two important characteristics of anti-capsular protective antibodies are i) 
high affinity and ii) a rim-type quellung reaction (36, 88-91). Affinity establishes 
how strongly an antibody binds its antigenic target; a high affinity antibody is 
more likely to remain bound to its target so it can perform effector functions, like 
complement activation or antibody-mediated opsonization. A quellung reaction is 
used to visualize how an antibody binds to a microbial capsule by differential 
interference contrast (DIC) microscopy (92). Antibodies can cross-link around the 
perimeter of the capsule, enclosing it in a tight rim or shell. Alternatively, they can 
bind throughout the capsule, leaving it open and puffy (93). 
 Rim-type patterns by microscopy correlate with antibody opsonization of 
the pathogenic yeast, Cryptococcus neoformans (94). This could be because it is 
easier for phagocytes to interact with antibodies binding at the capsular edge 
versus throughout the capsule. The C. neoformans capsule is very large and very 
fluid, making it difficult for phagocytes to interact with bound antibody FC 
receptors (94). Increasing phagocyte receptor mobility increases opsonization 





 High affinity, rim-type antibodies to the capsule of B. anthracis are 
protective (89). Subclass-switching a protective IgG3 to any other subclass (IgG1, 
IgG2b, IgG2a) results in an antibody that is low affinity and forms a puffy-type 
quellung reaction (98). As expected, the subclass-switch antibodies are non-
protective in a murine model of pulmonary anthrax. Additionally, when converting 
this same IgG3 mAb into human chimeric antibodies (chAbs), the resulting chAbs 
have greatly reduced affinity and produce a puffy-type quellung reaction (99). 
Subclass-switching the protective, anti-CPS IgG3 mAb, 3C5, yields similar 
results (Chapter 1). The IgG3 subclass is high affinity and is protective in a 
murine model of pulmonary melioidosis (median time-to-death (MDT) of 31 days) 
(36); the subclass-switch antibodies are low affinity, react poorly with CPS via 
ELISA, and provide significantly less protection (MTD of 4 days). Removal of the 
IgG3 FC region by proteolytic cleavage generates low affinity F(ab’)2 fragments 
that react with CPS poorly via ELISA. Subclass-switch antibodies are antibodies 
that have identical FV regions but different heavy chain constant regions. Thus, 
they bind to the exact same epitope, but have different effector functions. This 
suggests that something in the constant region is contributing to the drop in 
affinity and lack of protection. The constant region itself is not solely responsible 
for the IgG3’s high affinity; we have generated several high affinity IgG1 mAbs 
that react strongly with CPS on ELISA and are protective in a murine model of 




2A5, yields high affinity IgG2b and IgG2a antibodies with no significant drop in 
animal protection.  
One hypothesis for this is that our IgG3 mAb, 3C5, only has a high affinity 
because of the cooperative binding phenomena seen in IgG3 mAbs. The FC 
regions cross-link; cross-linking assists the antibodies in both binding to their 
target and remaining bound by keeping them in proximity to the antigen (100). 
Altering or removal of the IgG3 FC region eliminates cooperative binding and the 
affinity increase that it provides. This idea is supported by the fact that protective 
antibodies do not have to be of the IgG3 subclass. IgG1, IgG2b, and IgG2a variants 
of mAb 2A5 were all significantly protective in a murine model of pulmonary 
melioidosis (Chapter 1). Additionally, IgG1 mAbs targeting the capsule of C. 
neoformans can be generated with high affinity, can form a rim-type pattern, and 
be protective in a murine model of C. neoformans infection (88, 101, 102). 
Unfortunately, B. pseudomallei is too small to be visualized with DIC microscopy 
(2-5 µm length, 0.4-0.8 µm diameter). Thus, a quellung reaction could not be 
observed; however, we believe the IgG3 variant of mAb 3C5 may form a rim-type 
pattern and the subclass-switch mAbs may form a puffy-type pattern. 
Furthermore, we hypothesize that all of the 2A5 variants would form rim-type 
patterns. Taken together, these results indicate that protection is subclass-
independent. High affinity mAbs of all subclasses have been shown to be 
protective in a murine model of melioidosis. Thus, immunization strategies should 




Another goal of the present study was to generate a library of high affinity 
anti-CPS antibodies of different IgG subclasses for the diagnosis of melioidosis. 
Melioidosis is rampant in developing and resource poor nations in Southeast Asia 
and claims an estimated 250,000 lives each year (personal communication from 
Dr. Direk Limmathurotsakul). This is partially due to how difficult melioidosis is to 
diagnose; B. pseudomallei has been called “the great mimicker” patients present 
with symptoms similar to many other common infections (103). Rapid diagnosis 
of melioidosis is critical. Delays in treatment are associated with higher rates 
patient relapse and mortality (1). However, there has been limited success 
developing diagnostic methods that are both rapid and accessible to resource 
poor countries. Current methods are time consuming, expensive to implement, 
and inaccurate (10). As such, we previously developed a prototype Active 
Melioidosis Detect™ Lateral Flow Immunoassay using IgG3 mAb 3C5 (104). The 
AMD LFI was highly successful; it could detect CPS in patient samples and 
identify B. pseudomallei colonies picked from agar plates. Tests were 
inexpensive to produce and could be performed in 10 minutes.  
Unfortunately, there were some background issues believed to be 
occurring due to IgG3-IgG3 interactions. LFI assays are analogous to ELISA 
sandwich assays; an immobilized antibody binds to one side of the antigen while 
a second, labeled, antibody binds to the other side. Without addition of antigen, 
there should be no ELISA signal, however, the cross-linking ability of IgG3 mAbs 




Thus, one of the goals of the present study was to reduce the background signal 
of the AMD LFI. 
As previously mentioned, capsules are weakly immunogenic and do not 
elicit a strong humoral immune response. IgG3 is the predominant subclass in 
response to a polysaccharide antigen in mice (105-107). Therefore, we 
immunized mice with CPS-BSA glycoconjugate (27). Glycoconjugate vaccines 
are available for a wide variety of pathogens, including Haemophilus influenzae, 
Neisseria meningitidis, and Streptococcus pneumoniae. They conjugate the 
weakly immunogenic capsular structure with a highly immunogenic protein or 
toxoid in order to generate a strong humoral immune response and elicit 
immunological memory. The CPS-BSA glycoconjugate was highly effective; we 
were able to generate seven IgG1 mAbs that target the CPS of B. pseudomallei. 
Of the seven antibodies generated, one has a 3-fold lower affinity than 
mAb 3C5 (mAb 3B4), two have similar affinities to mAb 3C5 (mAb 1A2 and mAb 
2A5) and one has a five-fold greater affinity (mAb 4C4). Additionally, mAbs 3B4, 
1A2, and 2A5 all react similarly to mAb 3C5 in direct binding ELISA while mAb 
4C4 performed best. The three remaining mAbs had affinities that were too low to 
accurately assess. Additionally, they performed very poorly in direct antigen 
ELISAs. Of the low affinity antibodies two were IgM (mAb 2B3 and mAb 1D4) and 
one was an IgG1 (mAb 1D3). This was not wholly unexpected. IgM antibodies are 
typically rapidly generated, low-affinity first responders that have not had the 




affinity by forming polymers of pentamers and hexamers; however, we 
hypothesize that as with IgG3 mAbs, the polymeric nature of IgM mAbs would be 
detrimental to the AMD LFI, thus, we did not pursue additional studies with these 
mAbs. 
 In order to determine which mAbs might function best on an LFI, we tested 
our library via sandwich ELISA. Our hypothesis was that a higher affinity antibody 
would be able to detect smaller amounts of CPS in patient samples. Results were 
mixed. As expected, mAb 4C4 (5-fold greater affinity than 3C5) could detect 
smaller concentrations of CPS in samples. However, we noticed no pattern 
among the remaining mAbs. For example, mAb 2A5 (similar affinity to 3C5) 
performed four-fold worse while mAb 3B4 (3-fold lower affinity than 3C5) only 
performed 2-fold worse. Results were similar when we used the library to create 
LFIs. These results indicate that affinity does not directly correlate with LFI 
performance. 
 In summary, we have characterized a library of 15 mAbs, including 2 
subclass families, targeting the CPS of B. pseudomallei and determined some 
ideal characteristics for mAbs used in therapeutics and diagnostics. IgG3 is the 
default response to polysaccharide antigens in mice; however, therapeutic mAbs 
can be of any IgG subclass, as long as they have a high affinity. These results 
are in agreement with studies involving both B. anthracis and C. neoformans. 
Both IgG3 and non-IgG3 mAbs can be protective in a murine model of pulmonary 




Furthermore, IgG1 mAbs provide the highest rates of protection in a murine 
model of cryptococcal meningitis (101, 108).  
Be that as it may, IgG3 mAbs are not the best candidates for use in LFIs 
as they tend to self-aggregate and produce false positive results. IgG1 mAbs 
seem to work well; however, when there are multiple candidates, it is difficult to 
predict which mAb will function best based on affinity or ELISA alone. The mAbs 
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